Studienliteratur zu Leukämien

Literatur aus den Studien zur ALL, AML, CML

Akute lymphoblastische Leukämien-Ersterkrankung

Studienliteratur ALL-BFM

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Schieck M, Lentes J, Thomay K, Hofmann W, Behrens YL, Hagedorn M, Ebersold J, Davenport CF, Fazio G, Moericke A, Buchmann S, Alten J, Cario G, Schrappe M, Bergmann AK, Stanulla M, Steinemann D, Schlegelberger B, Cazzaniga G, Goehring G: Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia. Annals of hematology 2020, 99: 809 [PMID: 32078009] SCH2020a
  2. Wuerthwein G, Lanvers-Kaminsky C, Gerss J, Moericke A, Zimmermann M, Stary J, Smisek P, Attarbaschi A, Nath C, Zucchetti M, Rizzari C, Schrappe M, Boos J: Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. Therapeutic drug monitoring 2020, 42: 435 [PMID: 32022785] WUE2020
  3. Kroll M, Kaupat-Bleckmann K, Moerickel A, Altenl J, Schewel DM, Stanullal M, Zimmermann M, Schrappe M, Cario G: Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Haematologica 2020, 105: 1013 [PMID: 31371414] KRO2020
  4. Cario G, Leoni V, Conter V, Baruchel A, Schrappe M, Biondi A: BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. Haematologica 2020, Epup ahead of print [PMID: 32414845] CAR2020
  5. Krull K, Kunstreich M, Bronsema A, Bleckmann K, Classen CF, Erdlenbruch B, Jorch N, Kolb R, Leipold A, Moser O, Prokop A, Scheurlen W, Steinbach D, Klasen-Sansone J, Klee D, Escherich G, Moericke A, Schrappe M, Borkhardt A, Kuhlen M: Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy. Leukemia & lymphoma 2019, 60: 78 [PMID: 29718744] KRU2019
  6. Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M: Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica 2019, 104:e13-e16 [PMID: 30213832] BIO2019
  7. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG: Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of clinical oncology 2019, 37: 2246 [PMID: 31283407] PIE2019
  8. Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, Wuerthwein G, Silvestri D, Colombini A, Conter V, Biondi A, Schrappe M, Moericke A, Zimmermann M, von Stackelberg A, Linderkamp C, Frühwald MC, Legien S, Attarbaschi A, Reismüller B, Kasper D, Smisek P, Stary J, Vinti L, Barisone E, Parasole R, Micalizzi C, Zucchetti M, Boos J: Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica 2019, 104: 1812 [PMID: 30705097] RIZ2019
  9. Testi AM, Attarbaschi A, Valsecchi MG, Moericke A, Cario G, Niggli F, Silvestri D, Bader P, Kuhlen M, Parasole R, Putti MC, Lang P, Flotho C, Mann G, Rizzari C, Barisone E, Locatelli F, Linderkamp C, Lauten M, Suttorp M, Zimmermann M, Basso G, Biondi A, Conter V, Schrappe M, AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Muenster) Study Group: Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European journal of cancer (Oxford, England : 1990) 2019, 122: 61 [PMID: 31629941] TES2019
  10. Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Goehring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, Biondi A: Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica 2019, [PMID: 31601692] CAR2019
  11. Junk SV, Klein N, Schreek S, Zimmermann M, Moericke A, Bleckmann K, Alten J, Dagdan E, Cario G, Kratz CP, Schrappe M, Stanulla M: TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. Haematologica 2019, 104:e402-e405 [PMID: 31289210] JUN2019
  12. Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, Cazzaniga G, Colombini A, Flotho C, Kuhlen M, Lang P, Lauten M, Linderkamp C, Locatelli F, Lo Nigro L, Moericke A, Niggli F, Panzer-Gruemayer R, Parasole R, Peters C, Caterina Putti M, Rizzari C, Suttorp M, Valsecchi MG, Conter V, Schrappe M, on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Muenster) Study Group: Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia 2019 Dec 5; [PMID: 31806872] ATT2019
  13. Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V: Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018, 36: 244 [PMID: 29148893] SCH2018b
  14. Stanulla M, Dagdan E, Zaliova M, Moericke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M, TRANSCALL Consortium,International BFM Study Group: IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of clinical oncology 2018, 36: 1240 [PMID: 29498923] STA2018
  15. Fuhrmann S, Schabath R, Möricke A, Zimmermann M, Kunz JB, Kulozik AE, Ludwig WD, Schrappe M, Karawajew L, Ratei R: Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. British journal of haematology 2018, 183: 96 [PMID: 30028023] FUR2018
  16. Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Ariò M, Conter V, Schrappe M, Valsecchi MG, Biondi A: Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica 2018, 103: 107 [PMID: 29079599] CAZ2018
  17. Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe M, Basso G, International-BFM-FLOW-network: AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry. Part B, Clinical cytometry 2017 Feb 10; [PMID: 28187514] DWO2017
  18. Schütte P, Möricke A, Zimmermann M, Bleckmann K, Reismüller B, Attarbaschi A, Mann G, Bodmer N, Niggli F, Schrappe M, Stanulla M, Kratz CP: Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. European journal of medical genetics 2016, 59: 143 [PMID: 26732628] SCH2016a
  19. Bleckmann K, Schrappe M: Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. Br J Haematol 2016, [Epub ahead of print] [PMID: 26773444] BLE2016
  20. Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML: Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016, 30: 32 [PMID: 26202931] BOE2016
  21. van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, Sanchez de Toledo J, Rizzari C, Silverman LB, Whitlock JA: Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016, 101: 279 [PMID: 26928249] SLU2016
  22. Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R: Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia 2016, 30: 1184 [PMID: 26369984] DRI2016
  23. Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Güngör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T: Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica 2016, 101: 741 [PMID: 26869631] PRE2016
  24. Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M: Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016, 127: 2101 [PMID: 26888258] MOE2016
  25. Zuna J, Moericke A, Arens M, Koehler R, Panzer-Grümayer R, Bartram CR, Fischer S, Fronkova E, Zaliova M, Schrauder A, Stanulla M, Zimmermann M, Trka J, Stary J, Attarbaschi A, Mann G, Schrappe M, Cario G: Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia. British journal of haematology 2016, 173: 742 [PMID: 26913693] ZUN2016
  26. Schütte P, Möricke A, Zimmermann M, Bleckmann K, Reismüller B, Attarbaschi A, Mann G, Bodmer N, Niggli F, Schrappe M, Stanulla M, Kratz CP: Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. Eur J Med Genet 2015, S1769-721230063-X. [Epub ahead of print] [PMID: 26732628] SCH2015
  27. Tiphaine AB, Hjalgrim LL, Nersting J, Breitkreutz J, Nelken B, Schrappe M, Stanulla M, Thomas C, Bertrand Y, Leverger G, Baruchel A, Schmiegelow K, Jacqz-Aigrain E: Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. Eur J Pharm Sci 2015 Dec 2; 83: 1-7. [PMID: 26657824] TIP2015
  28. Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R: Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia 2015, Epub ahead of print [DOI: 10.1038/leu.2015.246] DRI2015
  29. Junk S, Cario G, Wittner N, Stanulla M, Scherer R, Schlegelberger B, Schrappe M, von Neuhoff N, Lauten M: Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. Klin Pädiatr 2015, 227: 123 [PMID: 25985447] JUN2015
  30. Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Möricke A, Schrappe M, Cario G: Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2015, 62: 1656 [PMID: 25833113] ALT2015
  31. Oevermann L, Firnkorn M, Michaelis S, Müller S, Schaeffeler E, Schrappe M, Cario G, Stanulla M, Schwab M, Handgretinger R, Mezger M: No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. Blood 2015, 125: 3355 [PMID: 25999446] OEV2015
  32. Kunz JB, Rausch T, Bandapalli OR, Eilers J, Pechanska P, Schuessele S, Assenov Y, Stütz AM, Kirschner-Schwabe R, Hof J, Eckert C, von Stackelberg A, Schrappe M, Stanulla M, Koehler R, Avigad S, Elitzur S, Handgretinger R, Benes V, Weischenfeldt J, Korbel JO, Muckenthaler MU, Kulozik AE: Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica 2015, 100: 1442 [PMID: 26294725] KUN2015
  33. Schrappe, M: Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 5; 2014, 244-9. [PMID: 25696862] SCH2014c
  34. Bandapalli OR, Schuessele S, Kunz JB, Rausch T, Stütz AM, Tal N, Geron I, Gershman N, Izraeli S, Eilers J, Vaezipour N, Kirschner-Schwabe R, Hof J, von Stackelberg A, Schrappe M, Stanulla M, Zimmermann M, Koehler R, Avigad S, Handgretinger R, Frismantas V, Bourquin JP, Bornhauser B, Korbel JO, Muckenthaler MU, Kulozik AE: The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 2014, Epub ahead of print [PMID: 24972766] BAN2014
  35. Attarbaschi A, Panzer-Grümayer R, Mann G, Möricke A, König M, Mecklenbräuker A, Teigler-Schlegel A, Bradtke J, Harbott J, Göhring G, Stanulla M, Schrappe M, Zimmermann M, Haas OA, Austrian and German ALL-BFM (Berlin-Frankfurt-Münster) Study Group: Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial. Klinische Padiatrie 2014, 226(6-7): 338 [PMID: 25431866] ATT2014
  36. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, Konja J, Kaiserova E, Kowalczyk J, Kovacs G, Li CK, Magyarosy E, Popa A, Stark B, Jabali Y, Trka J, Hrusak O, Riehm H, Masera G, Schrappe M: Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. Journal of clinical oncology 2014, 32: 174 [PMID: 24344215] STA2014
  37. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Biondi A, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grümayer R, Mondelaers V, Lammens T, Cavé H, Stark B, Ganmore I, Moorman AV, Vora A, Hunger SP, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk JR, Whitlock JA, Zwaan CM: Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 2014, 123: 70 [PMID: 24222333] BUI2014
  38. Bartram T, Burkhardt B, Wössmann W, Seidemann K, Zimmermann M, Cario G, Lisfeld J, Ellinghaus E, Franke A, Houlston RS, Schrappe M, Reiter A, Stanulla M: Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group. Leukemia & lymphoma 2014,: 1 [PMID: 25005032] BAR2014
  39. Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M: Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000. Klinische Padiatrie 2013, 225(S 01):S62-S72 [PMID: 23700060] SCH2013a
  40. Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, Koehler R, Muckenthaler MU, Kulozik AE: NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 2013, Epub ahead of print [PMID: 23349303] BAN2013
  41. Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T: Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity and outcome in childhood acute lymphoblastic leukemia. Blood 2013, Epub ahead of print [PMID: 23652803] RAD2013
  42. Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S: Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. Clinical cancer research 2013, 19: 1445 [PMID: 23357978] BAS2013
  43. Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M, Zimmermann M, Attarbaschi A, Niggli F, Schrappe M: Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia. Klinische Padiatrie 2013, 225(S 01):S50-S56 [PMID: 23700057] MOE2013
  44. Cario G, Rhein P, Mitloehner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L: High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013 Aug 2; E-pub ahead of print [PMID: 23911702] CAR2013
  45. Ratei R, Schabath R, Karawajew L, Zimmermann M, Möricke A, Schrappe M, Ludwig WD: Lineage Classification of Childhood Acute Lymphoblastic Leukemia according to the EGIL Recommendations: Results of the ALL-BFM 2000 Trial. Klinische Padiatrie 2013, 225(S 01):S8 [PMID: 23700065] RAT2013
  46. Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, Zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R: The MLL recombinome of acute leukemias in 2013. Leukemia 2013, Epub ahead of print [PMID: 23628958] MEY2013
  47. Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M: Optimizing asparaginase therapy for acute lymphoblastic leukemia. Current opinion in oncology 2013, 25 Suppl 1:S1 [PMID: 23380829] RIZ2013
  48. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012, 366: 1371 [PMID: 22494120] SCH2012a
  49. Stanulla M, Bourquin JP: Behandlung der akuten lymphoblastischen Leukämie im Kindesalter. Pharm unserer Zeit 2012, 3 [PMID: 22844667] STA2012
  50. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG: Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. The lancet oncology 2012, 13: 936 [PMID: 22898679] BIO2012
  51. Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M: Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica 2012, 97: 402 [PMID: 22058224] ZEI2012
  52. Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M: Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the trial ALL-BFM 95. Differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012, Epub ahead of print [PMID: 22271901] LAU2012
  53. Ellinghaus E, Stanulla M, Richter G, Ellinghaus D, Te Kronnie G, Cario G, Cazzaniga G, Horstmann M, Panzer Grümayer R, Cavé H, Trka J, Cinek O, Teigler-Schlegel A, Elsharawy A, Häsler R, Nebel A, Meissner B, Bartram T, Lescai F, Franceschi C, Giordan M, Nürnberg P, Heinzow B, Zimmermann M, Schreiber S, Schrappe M, Franke A: Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 2012, 26: 902 [PMID: 22076464] ELL2012
  54. Bartram CR, Schrauder A, Köhler R, Schrappe M: Akute lymphoblastische Leukämie bei Kindern (Übersichtsarbeit). Dtsch Arztebl Int 2012; 109: 652 [URI: http://www.aerzteblatt.de/ archiv/ 131461?s=%DCbersichtsarbeit] BAR2012
  55. Steinbach D, Wilhelm B, Kiermaier HR, Creutzig U, Schrappe M, Zimmermann M, Debatin KM, Gruhn B, von Stackelberg A, Jürgens H, Strahm B, Reinhardt D, Möricke A: 35. Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. Arch Dis Child 2011, [Epub ahead of print] [PMID: 21719441] STE2011a
  56. Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B, Mirkowska P, Tchinda J, Niggli FK, Stanulla M, Schrappe M, Schrauder A, Bornhauser BC, Bourquin JP: Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 2011,Epub ahead of print [PMID: 21670474] SCH2011a
  57. Eckert C, Flohr T, Koehler R, Hagedorn N, Moericke A, Stanulla M, Kirschner-Schwabe R, Cario G, Stackelberg A, Bartram CR, Henze G, Schrappe M, Schrauder A: Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia 2011, May, Epub ahead of print [PMID: 21546902] ECK2011
  58. Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C: Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011, 118: 5774 [PMID: 21940824] WIL2011
  59. Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J: Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatric blood & cancer 2010, 54: 952 [PMID: 20108339] SCH2010a
  60. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia : 2010, 24: 265 [PMID: 20010625] MOE2010
  61. Hempel G, Müller HJ, Lanvers-Kaminsky C, Würthwein G, Hoppe A, Boos J: A population pharmacokinetic model for pegylated-asparaginase in children. British journal of haematology 2010, 148: 119 [PMID: 19821822] HEM2010
  62. Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A, Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. British journal of haematology 2010, 149: 93 [PMID: 20067563] PIC2010
  63. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115: 3206 [PMID: 20154213] CON2010
  64. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, [PMID: 20378752] CAR2010
  65. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ, European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL),International Berlin-Frankfurt-Münster Study Group (I-BFM-SG): Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24: 521 [PMID: 20033054] BRU2010
  66. Krieger D, Moericke A, Oschlies I, Zimmermann M, Schrappe M, Reiter A, Burkhardt B: Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica 2010, 95: 158 [PMID: 19586936] KRI2010
  67. Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH: 'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia 2010, 24: 253 [PMID: 20145664] SCH2010
  68. Staege MS, Körholz D: New treatment strategies for Hodgkin's lymphoma. Leukemia research 2009, 33: 886 [PMID: 19233468] STA2009b
  69. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, AIEOP-BFM-FCM-MRD-Study Group: Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009, 23: 528 [PMID: 19020543] RAT2009
  70. Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood 2009, 114: 1314 [PMID: 19535798] STA2009
  71. Kidas E, Möricke A, Beier R, Welte K, Schrappe M, Stanulla M, Grigull L: Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. International journal of hematology 2009, 89: 584 [PMID: 19353239] KID2009
  72. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, Werft W, Breit S, Liu S, Engel F, Wittmann A, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Bartram CR, Radlwimmer B, Muckenthaler MU, Lichter P, Kulozik AE: High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16. 1 as a genomic marker for unfavorable early treatment response. Blood 2009, 114: 1053 [PMID: 19406988] REM2009
  73. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, Pui CH: The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia 2009, 23: 2318 [PMID: 19890375] BIO2009
  74. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ, Interfant-99 Study Group: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009, 23: 1073 [PMID: 19212338] VEL2009
  75. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiation protection dosimetry 2008, 132: 130 [PMID: 19017727] SCH2008d
  76. Schrappe M, Creutzig U: Akute lymphoblastische (ALL) und akute myeloische (AML) Leukämie im Kindesalter. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie. AWMF online 2008 [URI: http://www.awmf.org/ uploads/ tx_szleitlinien/ 025-014_abgelaufen.pdf] SCH2008a
  77. Cario G, Fetz A, Bretscher C, Möricke A, Schrauder A, Stanulla M, Schrappe M: Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Annals of hematology 2008, 87: 709 [PMID: 18521602] CAR2008
  78. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Münster (ALL-BFM) trials. Journal of clinical oncology 2008, 26: 3046 [PMID: 18565891] ATT2008
  79. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG): Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008, 22: 771 [PMID: 18239620] FLO2008
  80. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leukemia & lymphoma 2008, 49: 451 [PMID: 18297521] BUR2008
  81. Teuffel O, Stanulla M, Cario G, Ludwig WD, Rottgers S, Schafer BW, Zimmermann M, Schrappe M, Niggli FK: Anemia and survival in childhood acute lymphoblastic leukemia. Haematologica 2008, 93: 1652 [PMID: 18815194] TEU2008
  82. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111: 4477 [PMID: 18285545] MOE2008
  83. Mann G, Cazzaniga G, van der Velden VH, Flohr T, Csinady E, Paganin M, Schrauder A, Dohnal AM, Schrappe M, Biondi A, Gadner H, van Dongen JJ, Panzer-Grümayer ER: Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease? Leukemia 2007, 21: 642 [PMID: 17287854] MAN2007
  84. Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schünemann HJ, Schlegelberger B, Schrappe M, Stanulla M: High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. Journal of clinical oncology 2007, 25: 4813 [PMID: 17947730] CAR2007
  85. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, Gadner H, Stary J, Benoit Y, Zimmermann M, Reiter A, Riehm H, Masera G, Schrappe M: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007, 369: 123 [PMID: 17223475] CON2007
  86. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370: 240 [PMID: 17658395] PIE2007
  87. Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M: Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. Blood cells, molecules & diseases 2007, 39: 160 [PMID: 17532236] STA2007
  88. Bürger B, Zimmermann M, Mann G, Kühl J, Loning L, Riehm H, Reiter A, Schrappe M: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21: 184 [PMID: 12525508] BUE2003
  89. Schrappe M, Beier R, Burger B: New treatment strategies in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002, 15: 729 [PMID: 12617873] SCH2002h
  90. Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M: Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Pädiatr 2001, 213: 169 [PMID: 11528550] LAU2001
  91. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W, Henze G, Gadner H, Odenwald E, Riehm H: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000, 14: 2205 [PMID: 11187912] SCH2000f
  92. Schrappe M, Reiter A, Ludwig W, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy. Blood 2000, 95: 3310 [PMID: 10828010] SCH2000e
  93. Stanulla M, Schrappe M, Brechlin A, Zimmermann M, Welte K: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2000, 95: 1222 [PMID: 10666194] STA2000a
  94. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352: 1731 [PMID: 9848348] DON1998

Studienliteratur CO-ALL

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Zur Stadt U, Alawi M, Adao M, Indenbirken D, Escherich G, Horstmann MA: Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL. Blood cancer journal 2019, 9: 96 [PMID: 31784504] STA2019
  2. Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, Hough R, Jeha S, Kato M, Liang DC, Mikkelsen TS, Möricke A, Niinimäki R, Piette C, Putti MC, Raetz E, Silverman LB, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E, Ponte di Legno toxicity working group: Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. The Lancet. Oncology 2016, 17:e231 [PMID: 27299279] SCH2016c
  3. Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML: Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016, 30: 32 [PMID: 26202931] BOE2016
  4. Kloos RQ, Pieters R, Escherich G, van der Sluis IM: Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation. Pediatric blood & cancer 2016, 63: 1928 [PMID: 27376478] KLO2016
  5. Vora A, Andreano A, Pui CH, Hunger SP, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman LB, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi MG: Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. Journal of clinical oncology 2016, 34: 919 [PMID: 26755523] VOR2016
  6. van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, Sanchez de Toledo J, Rizzari C, Silverman LB, Whitlock JA: Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016, 101: 279 [PMID: 26928249] SLU2016
  7. Stapleton JL, Tatum KL, Devine KA, Stephens S, Masterson M, Baig A, Hudson SV, Coups EJ: Skin Cancer Surveillance Behaviors Among Childhood Cancer Survivors. Pediatric blood & cancer 2016, 63: 554 [PMID: 26513138] STA2016
  8. Kloos RQ, Pieters R, Escherich G, van der Sluis IM: Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation. Pediatric blood & cancer 2016, 63: 1928 [PMID: 27376478] KLO2016
  9. Löbel U, Trah J, Escherich G: Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2015, 62: 539 [PMID: 25360802] LOE2015
  10. Escherich G, Zur Stadt U, Zimmermann M, Horstmann MA, on behalf of the CoALL study group: Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial. British journal of haematology 2013, epub ahead of print [PMID: 23937310] ESH2013
  11. Escherich G, Troeger AF, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer ML, Janka-Schaub G: The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011, Epub ahead of print [PMID: 21330320] ESC2011
  12. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL study group: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia : 2010, 24: 298 [PMID: 20016530] ESC2010
  13. Krappmann P, Paulides M, Stöhr W, Ittner E, Plattig B, Nickel P, Lackner H, Schrappe M, Janka G, Beck JD, Langer T: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatric hematology and oncology 2007, 24: 101 [PMID: 17454775] KRA2007a
  14. Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE: Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klinische Padiatrie 2007, 219: 134 [PMID: 17525906] ESC2007
  15. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka GE: Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatric blood & cancer 2008, 50: 259 [PMID: 17635005] GRA2007
  16. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, Veerman AJ, van Wering ER, van Noesel MM, Pieters R: The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006, 91: 1212 [PMID: 16956820] GRO2006
  17. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R: Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clinical cancer research 2005, 11: 2974 [PMID: 15837750] STA2005a
  18. Khalil MN, Erb N, Khalil PN, Escherich G, Janka-Schaub GE: Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005, 821: 105 [PMID: 15897017] KHA2005
  19. Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, Janka-Schaub GE, Evans WE, Pieters R: Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005, 105: 4223 [PMID: 15718422] STA2005
  20. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 2005, 106: 1817 [PMID: 15899912] HOL2005
  21. Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H: DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach. International journal of oncology 2005, 27: 547 [PMID: 16010438] ZUS2005
  22. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE: Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer cell 2005, 7: 375 [PMID: 15837626] LUG2005
  23. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. The New England journal of medicine 2004, 351: 533 [PMID: 15295046] HOL2004
  24. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R: In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004, 18: 521 [PMID: 14712291] RAM2004

Akute lymphoblastische Leukämie-Rezidive

Studienliteratur ALL-Rezidiv

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Barz MJ, Hof J, Groeneveld-Krentz S, Loh JW, Szymansky A, Astrahantseff K, von Stackelberg A, Khiabanian H, Ferrando AA, Eckert C, Kirschner-Schwabe R: Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood 2020, 135: 921 [PMID: 31971569] BAR2020
  2. Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin JP, Peters C, Henze G, von Stackelberg A, ALL-REZ BFM Trial Group: Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of clinical oncology 2019 Dec 20; 37: 3493 [PMID: 31644328] ECK2019a
  3. Groeneveld-Krentz S, Schroeder MP, Reiter M, Pogodzinski MJ, Pimentel-Gutierrez HJ, Vagkopoulou R, Hof J, Chen-Santel C, Nebral K, Bradtke J, Tuerkmen S, Baldus CD, Gattenloehner S, Haas OA, von Stackelberg A, Karawajew L, Eckert C, Kirschner-Schwabe R: Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse. British journal of haematology 2019, 185: 266 [PMID: 30714092] GRO2019
  4. Hoell JI, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, Zur Stadt U, Bader P, Babor F, Schuster F, Strahm B, Alten J, Moericke A, Escherich G, von Stackelberg A, Thiele R, McHardy AC, Peters C, Bornhauser B, Bourquin JP, Krause S, Enczmann J, Meyer LH, Eckert C, Borkhardt A, Meisel R: Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood advances 2019, 3: 3143 [PMID: 31648313] HOE2019
  5. Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin JP, Peters C, Henze G, von Stackelberg A, ALL-REZ BFM Trial Group: Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of clinical oncology 2019 Dec 20; 37: 3493 [PMID: 31644328] ECK2019
  6. Kuhlen M, Bader P, Sauer M, Albert MH, Gruhn B, Güngür T, Kropshofer G, Lang P, Lawitschka A, Metzler M, Pentek F, Rossig C, Schlegel PG, Schrappe M, Schrum J, Schulz A, Schwinger W, von Stackelberg A, Strahm B, Suttorp M, Luettichau IT, Wössmann W, Borkhardt A, Meisel R, Poetschger U, Glogova E, Peters C: Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial. British journal of haematology 2018, 183: 104 [PMID: 30028016] KUH2018
  7. Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A: Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia 2015, 29: 1648 [PMID: 25748682] ECK2015
  8. Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, Basso G, Hrusak O, Ludwig WD, Henze G, Seeger K, von Stackelberg A, Mejstrikova E, Eckert C: Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica 2015, 100: 935 [PMID: 26001791] KAR2015
  9. Bokemeyer A, Eckert C, Meyr F, Koerner G, von Stackelberg A, Ullmann R, Türkmen S, Henze G, Seeger K: Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. Haematologica 2014, 99: 706 [PMID: 24241490] BOK2014
  10. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C: Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014, 124: 3420 [PMID: 25253770] IRV2014
  11. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A: Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. Journal of clinical oncology 2013, 31: 2736 [PMID: 23775972] ECK2013a
  12. Reismüller B, Peters C, Dworzak MN, Pötschger U, Urban C, Meister B, Schmitt K, Dieckmann K, Gadner H, Attarbaschi A, Mann G, on behalf of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group: Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL): A Population-based Analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Journal of pediatric hematology/oncology 2013, Epub ahead of print [PMID: 23652878] REI2013a
  13. Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C, Schrappe M, Henze G, von Stackelberg A, Hitzler J: Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. British journal of haematology 2013, Epub ahead of print [PMID: 23594030] MEY2013a
  14. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G: Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. European journal of cancer 2013, 49: 1346 [PMID: 23265714] ECK2013
  15. Henze G, v Stackelberg A, Eckert C: ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. Klinische Padiatrie 2013, 225 Suppl 1:S73 [PMID: 23700062] HEN2013
  16. Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TW, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, Kirschner-Schwabe R: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2013, 27: 295 [PMID: 22699455] KRE2013
  17. Tallen G, Henze G, von Stackelberg A: Treatment of children and adolescents with relapsed ALL: therapy target long-term healing. Pharm Unserer Zeit 2012, 41: 214 [PMID: 22844668] TAL2012
  18. Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TW, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, Kirschner-Schwabe R: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2013, 27: 295 [PMID: 22699455] KRE2012
  19. Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, Henze G, von Stackelberg A, Seeger K: High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 2011, 96: 1627 [PMID: 21828124] SHA2011a
  20. Eckert C, Flohr T, Koehler R, Hagedorn N, Moericke A, Stanulla M, Kirschner-Schwabe R, Cario G, Stackelberg A, Bartram CR, Henze G, Schrappe M, Schrauder A: Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia 2011, May, Epub ahead of print [PMID: 21546902] ECK2011
  21. Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R: Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia. J Clin Oncol 2011, [Epub ahead of print] [PMID: 21747090] HOF2011
  22. Balduzzi A, Galimberti S, Valsecchi MG, Bonanomi S, Conter V, Barth A, Rovelli A, Henze G, Biondi A, von Stackelberg A: Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Pediatric blood & cancer 2011, 57: 654 [PMID: 21584934] BAL2011
  23. Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C: Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011, 118: 5774 [PMID: 21940824] WIL2011
  24. von Stackelberg A, Völzke E, Kühl JS, Seeger K, Schrauder A, Escherich G, Henze G, Tallen G, for the ALL-REZ BFM Study Group: Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. European journal of cancer 2011, 47: 90 [PMID: 20970323] STA2010
  25. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A: Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Journal of clinical oncology 2010, 28: 2339 [PMID: 20385996] TAL2010
  26. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T: Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. Journal of molecular medicine 2010, 88: 249 [PMID: 20155409] SHA2010
  27. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A: Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2010 Oct 14; [PMID: 20944674] HAN2010
  28. Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S: The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia 2010 Nov 12; [PMID: 21072050] BAS2010
  29. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of clinical oncology 2009, 27: 377 [PMID: 19064980] BAD2009
  30. von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G, ALL-REZ BFM Study Group: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 2008, 111: 2573 [PMID: 18089849] STA2008a
  31. Borgmann A, Zinn C, Hartmann R, Herold R ,Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. European journal of cancer (Oxford, England : 1990) 2008, 44: 257 [PMID: 17981026] BOR2008
  32. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hahlen K, Göbel U, Klingebiel T, Ludwig WD, Henze G: Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Journal of clinical oncology 2005, 23: 7942 [PMID: 16258094] EIN2005
  33. Wellmann S, Moderegger E, Zelmer A, Bettkober M, von Stackelberg A, Henze G, Seeger K: FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse. Leukemia 2005, 19: 467 [PMID: 15674414] WEL2005
  34. Wagner-Bohn A, Henze G, von Stackelberg A, Boos J: Phase II study of gemcitabine in children with relapsed leukemia. Pediatric blood & cancer 2006, 46: 262 [PMID: 16331664] WAG2005
  35. Nenning UC, Eckert C, Wellmann S, Barth A, Henze G, Seeger K: Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. Journal of the National Cancer Institute 2005, 97: 1091-2; author reply 1093 [PMID: 16030311] NEN2005
  36. Henze G: 20 Jahre Studien zur Behandlung von Kindern mit Rezidiv einer akuten lymphoblastischen Leukämie (ALL-REZ BFM). WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2004, 3: 13 [URI: http://www.kinderkrebsstiftung.de/ fileadmin/ KKS/ files/ zeitschriftWIR/ 2004_3/ ALL-REZ.pdf] HEN2004a

Akute lymphoblastische Leukämien-Stammzelltransplantation

Studienliteratur Stammzelltransplantation bei ALL

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Güngör T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M, IBFM Study Group,, von Stackelberg A, IntReALL Study Group, Balduzzi A, I-BFM SCT Study Group, Corbacioglu S, EBMT Paediatric Diseases Working Party, Bader P: Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021, 39: 295 [PMID: 33332189] PET2021a
  2. Lawitschka A, Lucchini G, Strahm B, Dalle JH, Balduzzi A, Gibson B, Diaz De Heredia C, Wachowiak J, Dalissier A, Vettenranta K, Yaniv I, Bordon V, Bauer D, Bader P, Meisel R, Peters C, Corbacioglu S, European Society for Blood, Marrow Transplantation (EBMT) Pediatric Diseases Working Party: Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations. Transplant international 2020, Epup ahead of print [PMID: 32133691] LAW2020
  3. Willasch AM, Peters C, Sedláček P, Dalle JH, Kitra-Roussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Kriván G, Hamladji RM, Diaz-de-Heredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, Veys P, Dupont S, Or R, Güngör T, Aleinikova O, Sufliarska S, Sundin M, Rascon J, Kaare A, Nemet D, Fagioli F, Klingebiel TE, Styczynski J, Bierings M, Nagy K, Abecasis M, Afanasyev B, Ansari M, Vettenranta K, Alseraihy A, Chybicka A, Robinson S, Bertrand Y, Kupesiz A, Ghavamzadeh A, Campos A, Pichler H, Dalissier A, Labopin M, Corbacioglu S, Balduzzi A, Galimard JE, Bader P, EBMT Paediatric Diseases Working Party: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone marrow transplantation 2020, Epup ahead of print [PMID: 32203263] WIL2020
  4. Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitra-Roussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Kriván G, Hamladji RM, Diaz-de-Heredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, Veys P, Dupont S, Or R, Güngör T, Aleinikova O, Sufliarska S, Sundin M, Rascon J, Kaare A, Nemet D, Fagioli F, Klingebiel TE, Styczynski J, Bierings M, Nagy K, Abecasis M, Afanasyev B, Ansari M, Vettenranta K, Alseraihy A, Chybicka A, Robinson S, Bertrand Y, Kupesiz A, Ghavamzadeh A, Campos A, Pichler H, Dalissier A, Labopin M, Corbacioglu S, Balduzzi A, Galimard JE, Bader P, EBMT Paediatric Diseases Working Party: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone marrow transplantation 2020, Epup ahead of print [PMID: 32203263] WIL2020
  5. Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, Sufliarska S, Balduzzi A, Strahm B, von Luettichau I, Hoell JI, Borkhardt A, Klingebiel T, Schrappe M, von Stackelberg A, Glogova E, Poetschger U, Meisel R, Peters C: Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. British journal of haematology 2018, 180: 82 [PMID: 29193007] KUH2018a
  6. Boztug H, Sykora KW, Slatter M, Zecca M, Veys P, Lankester A, Cant A, Skinner R, Wachowiak J, Glogova E, Pötschger U, Peters C: European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatr Blood Cancer 2016, 63: 139 [PMID: 26398915] BOZ2016
  7. Witt V, Pichler H, Fritsch G, Peters C: Multiple small versus few large amount aspirations for bone marrow harvesting in autologous and allogeneic bone marrow transplantation. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2016, 55: 221 [PMID: 27452644] WIT2016
  8. Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Güngör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T: Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica 2016, 101: 741 [PMID: 26869631] PRE2016
  9. Bresters D, Lawitschka A, Cugno C, Pötschger U, Dalissier A, Michel G, Vettenranta K, Sundin M, Al-Seraihy A, Faraci M, Sedlacek P, Versluys AB, Jenkins A, Lutz P, Gibson B, Leiper A, Diaz MA, Shaw PJ, Skinner R, O'Brien TA, Salooja N, Bader P, Peters C: Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone marrow transplantation 2016, 51: 1482 [PMID: 27348540] BRE2016
  10. Slatter MA, Boztug H, Pötschger U, Sykora KW, Lankester A, Yaniv I, Sedlacek P, Glogova E, Veys P, Gennery AR, Peters C: Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant 2015, 50: 1536 [PMID: 26259076] SLA2015
  11. Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N: Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant 2015, 50: 1542 [PMID: 26367221] RUU2015
  12. Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert MH, Willasch AM, Klingebiel TE, Peters C: Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, epub ahead of print [PMID: 25605857] BAD2015
  13. Lawitschka A, Faraci M, Yaniv I, Veys P, Bader P, Wachowiak J, Socie G, Aljurf MD, Arat M, Boelens JJ, Duarte R, Tichelli A, Peters C: Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. Bone marrow transplantation 2015, epub ahead of print [PMID: 25621804] LAW2015
  14. Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T: Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. Journal of clinical oncology 2015, 33: 1265 [PMID: 25753432] PET2015
  15. Fazekas T, Attarbaschi A, Lawitschka A, Seidel M, Pötschger U, Peters C, Mann G, Gadner H, Matthes-Martin S: Lethal pulmonary complications after pediatric allogeneic hematopoietic stem cell transplantation. The Pediatric infectious disease journal 2012, 31: 115 [PMID: 21909046] FAZ2012a
  16. Lawitschka A, Ball L, Peters C: Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents. Biology of blood and marrow transplantation 2012, 18(1 Suppl):S74-81. [PMID: 22226116] LAW2012
  17. Ruggeri A, Michel G, Dalle JH, Caniglia M, Locatelli F, Campos A, Diaz de Heredia C, Mohty M, Perez Hurtado JM, Bierings M, Bittencourt H, Mauad M, Purtill D, Cunha R, Kabbara N, Gluckman E, Labopin M, Peters C, Rocha V: Impact of pre-transplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission. An Eurocord, PDWP-EBMT analysis. Leukemia 2012, [Epub ahead of print] [DOI: 10.1038/leu.2012.123] RUG2012
  18. Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, Lawitschka A, Peters C, Mann G, Lion T, Matthes-Martin S: Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2012, 26: 509 [PMID: 21926962] BRE2012
  19. Fazekas T, Eickhoff P, Lawitschka A, Knotek B, Pötschger U, Peters C: Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation. European journal of pediatrics 2012 Feb 16; [PMID: 22350283] FAZ2012
  20. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, Müller I, Stein J, Wynn R, Greil J, Sykora KW, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin KM, Peters C, Dini G: Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012, 379: 1301 [PMID: 22364685] COR2012
  21. Wachowiak J, Sykora KW, Cornish J, Chybicka A, Kowalczyk JR, Gorczyńska E, Choma M, Grund G, Peters C: Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant 2011, Epub ahead of print [PMID: 21297673] WAC2011
  22. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R: Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukaemia: results from the Interfant-99 Study. Blood 2010 Jun 30; [Epub ahead of print] [PMID: 20592248] MAN2010
  23. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernández-Viña M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Müller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J: An update to HLA Nomenclature, 2010. Bone marrow transplantation 2010, 45: 846 [PMID: 20348972] MAR2010
  24. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V, Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT): Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010, 115: 3437 [PMID: 20040760] KLI2010
  25. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of clinical oncology 2009, 27: 377 [PMID: 19064980] BAD2009
  26. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C, ALL-BFM Study Group, EBMT PD WP, I-BFM Study Group: Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone marrow transplantation 2008, 41 Suppl 2:S71 [PMID: 18545248] SCH2008b
  27. Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica 2008, 93: 925 [PMID: 18413892] BAL2008
  28. Kircher B, Niederwieser D, Gächter A, Lindner B, Mitterschiffthaler A, Urban C, Greinix H, Peters C, Lätzer K, Gastl G, Nachbaur D: T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. International journal of laboratory hematology 2008, 30: 499 [PMID: 18522713] KIR2008
  29. Lanino E, Sacchi N, Peters C, Giardino S, Rocha V, Dini G, EBMT Paediatric, Acute Leukemia Working Parties, Eurocord: Strategies of the donor search for children with second CR ALL lacking a matched sibling donor. Bone marrow transplantation 2008, 41 Suppl 2:S75 [PMID: 18545249] LAN2008
  30. Dini G, Locatelli F, Peters C, Wachowiak J, EBMT Paediatric Diseases: Proceedings of the 6th Meeting of the EBMT Paediatric Diseases Working Party and 1st Meeting of the EBMT Paediatric Nurses. Introduction. Bone marrow transplantation 2008, 42 Suppl 2:S1 [PMID: 18978734] DIN2008
  31. Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M: Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone marrow transplantation 2007, 40: 945 [PMID: 17768387] MEI2007
  32. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G, Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation: Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation 2007, 39: 89 [PMID: 17213848] MIA2007
  33. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. Journal of clinical oncology 2006, 24: 5742 [PMID: 17179108] SCH2006a
  34. Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Pötschger U, Rosenmayr A, Fischer G, Gadner H, Peters C: In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica 2005, 90: 1405 [PMID: 16219578] SEI2005a
  35. Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I, Gadner H, Klingebiel T, BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT: Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone marrow transplantation 2005, 35 Suppl 1:S9 [PMID: 15812540] PET2005
  36. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005, 366: 635 [PMID: 16112299] BAL2005
  37. Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, Frommlet F, Gadner H, Peters C: Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone marrow transplantation 2003, 31: 803 [PMID: 12732888] MAT2003

Akute myeloische Leukämie-Ersterkrankung und Rezidive

Studienliteratur AML

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M: Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. Haematologica 2019, 104: 120 [PMID: 30093401] NIK2019
  2. Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U, Klusmann JH, Reinhardt D: Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018, 32: 2167 [PMID: 29550834] RAS2018
  3. Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, Scheffers L, Hasle H, Zwaan CM, Reinhardt D, Klusmann JH: Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood 2017 Jun 22; 129: 3314 [PMID: 28400376] UFF2017
  4. Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N: First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatric blood & cancer 2017, Epub ahead of print [PMID: 28111878] CRE2017
  5. Rasche M, von Neuhoff C, Dworzak M, Bourquin JP, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas OA, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D: Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. Leukemia 2017, 31: 2807 [PMID: 28443606] RAS2017
  6. Göhring G, Thomay K, Schmidt G, Ripperger T, Xu M, Wittner N, Chao MM, Baumann I, Niewisch M, Reinhardt D, Klingebiel T, Thol F, Schlegelberger B, Niemeyer CM: A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl. Leukemia & lymphoma 2017, 58: 718 [PMID: 27892742] GOE2017
  7. Scheer C, Kratz C, Witt O, Creutzig U, Reinhardt D, Klusmann JH: Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. Pediatric blood & cancer 2016, 63: 1677 [PMID: 27191354] SCH2016d
  8. Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C: Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer 2016, 122: 3821 [PMID: 27529519] CRE2016c
  9. Hassler A, Bochennek K, Gilfert J, Perner C, Schöning S, Creutzig U, Reinhardt D, Lehrnbecher T: Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. Pediatr Blood Cancer 2016, [Epub ahead of print] [PMID: 26814618] HAS2016
  10. Bochennek K, Hassler A, Perner C, Gilfert J, Schöning S, Klingebiel T, Reinhardt D, Creutzig U, Lehrnbecher T: Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J 2016, 15; 6:e382 [PMID: 26771808] BOC2016
  11. Abla O, Kutny MA, Testi AM, Feusner JH, Creutzig U, Gregory J Jr, Gibson B, Leverger G, Ribeiro RC, Smith O, Locatelli F, Kaspers G: Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. British journal of haematology 2016, 175: 588 [PMID: 27651168] ABL2016
  12. Tramsen L, Salzmann-Manrique E, Bochennek K, Klingebiel T, Reinhardt D, Creutzig U, Sung L, Lehrnbecher T: Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016, 34: 2776 [PMID: 27269945] TRA2016
  13. Creutzig U, Dworzak MN, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Stackelberg AV, Starý J, Reinhardt D: Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival. Leukemia 2015, 29: 2260 [PMID: 25869725] CRE2015b
  14. Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, Reinhardt D, Klusmann JH: Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Journal of the European Academy of Dermatology and Venereology : JEADV SCH2015b
  15. Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, von Stackelberg A, Stray J, Reinhardt D: Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Klin Pädiatr 2015, 227: 116 [PMID: 25985446] CRE2015a
  16. Kremeike K, Juergens C, Alz H, Reinhardt D: Patients' Adherence in the Maintenance Therapy of Children and Adolescents with Acute Lymphoblastic Leukemia. Klin Pädiatr 2015, 227(6-07): 329 [PMID: 26457956] KRE2015
  17. Creutzig U, Rössig C, Dworzak M, Stary J, von Stackelberg A, Wössmann W, Zimmermann M, Reinhardt D: Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. Pediatr Blood Cancer 2015 [Epub ahead of print] [PMID: 26670831] CRE2015
  18. Creutzig U, Semmler J, Kaspers GL, Reinhardt D, Zimmermann M: Re-induction with L-DNR/FLAG improves response after AML relapse, but not long-term survival. Klinische Padiatrie 2014, 226(6-7): 323 [PMID: 25431865] CRE2014a
  19. Steinbach D, Bader P, Willasch A, Bartholomae S, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, Gruhn B: Prospective validation of a new method of monitoring minimal residual disease in childhood acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2014, epub ahead of print [PMID: 25501127] STE2014
  20. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Stary J, Reinhardt D: Randomized trial comparing liposomal daunorubicin with idarubicin in induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013, 122: 37 [PMID: 23704089] CRE2013b
  21. Creutzig U, Tallen G: Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries. memo 2013 6: 5 [URI: http://link.springer.com/ article/ 10.1007/ s12254-013-0070-3/ fulltext.html] CRE2013
  22. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dell'Adulto, German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369: 111 [PMID: 23841729] COC2013
  23. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D, AML Committee of the International BFM Study Group: Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012, 120: 3187 [PMID: 22879540] CRE2012a
  24. Reinhardt D, Reinhardt K, Neuhoff C, Sander A, Klusmann JH, Pekrun A, Sauerbrey A, von Stackelberg A, Rössig C, Creutzig U, Kolenova A: [GATA1-Mutation Associated Leukemia in Children with Trisomy 21 Mosaic]. Klinische Padiatrie 2012, 224: 153 [PMID: 22513796] REI2012
  25. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D: Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011, 118: 5409 [PMID: 21948298] CRE2011c
  26. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Starý J, Steinbach D, Vormoor J, Reinhardt D: Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012, 26: 654 [PMID: 21968880] CRE2011b
  27. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, Sander A, Schrauder A, von Stackelberg A, Ritter J, Starý J, Reinhardt D: CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011, [Epub ahead of print] [PMID: 21480469] CRE2011
  28. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T: The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012, 97: 21 [PMID: 21933851] KLU2011
  29. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ, International BFM Study Group on Paediatric AML: Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British journal of haematology 2010, 148: 768 [PMID: 19995399] ZWA2010a
  30. Balgobind BV, Hollink IH, Reinhardt D, van Wering ER, de Graaf SS, Baruchel A, Stary J, Beverloo HB, de Greef GE, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM: Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. European journal of cancer 2010, [PMID: 20233657] BAL2010a
  31. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ, Creutzig U: Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010 [PMID: 20535146] SAN2010
  32. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ: A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010, [PMID: 20538803] NIE2010
  33. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U: Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. Journal of clinical oncology 2010, 28: 2682 [PMID: 20439630] NEU2010
  34. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British journal of haematology 2010, 149: 399 [PMID: 20230404] CRE2010
  35. Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D: Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. Journal of clinical oncology 2010, 28: 2591 [PMID: 20406937] EHL2010
  36. Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hählen K, Gibson BE, Creutzig U, Kaspers GJ: FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leukemia research 2010, [PMID: 20435347] GOE2010
  37. Klusmann JH, Li Z, Böhmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D: miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes & development 2010, 24: 478 [PMID: 20194440] KLU2010
  38. Zwaan CM, Reinhardt D, Hitzler J, Vyas P: Acute leukemias in children with Down syndrome. Hematology/oncology clinics of North America 2010, 24: 19 [PMID: 20113894] ZWA2010
  39. Gerr H, Zimmermann M, Schrappe M, Dworzak M, Ludwig WD, Bradtke J, Moericke A, Schabath R, Creutzig U, Reinhardt D: Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. British journal of haematology 2010, 149: 84 [PMID: 20085575] GER2010
  40. Meyer LH, Queudeville M, Eckhoff SM, Creutzig U, Reinhardt D, Karawajew L, Ludwig WD, Stahnke K, Debatin KM: Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood 2008, 111: 2899 [PMID: 18083847] MEY2008a
  41. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, Kaspers GJ, de Graaf SS, Harbott J, Creutzig U, Reinhardt D, van den Heuvel-Eibrink MM, Thiede C: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009, 23: 262 [PMID: 19020547] HOL2008a
  42. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D: Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood 2008, 111: 2991 [PMID: 18182574] KLU2008
  43. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF: Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008, 112: 562 [PMID: 18076087] CRE2008
  44. Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U: Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 2007, 109: 936 [PMID: 17008536] LEH2007
  45. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D: Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric blood & cancer 2007, 48: 651 [PMID: 17183582] CRE2007
  46. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D: Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Journal of clinical oncology 2006, 24: 4499 [PMID: 16983120] CRE2006b
  47. Reinhardt D, Ritter J: Reaktive Veränderungen des Blutbildes und des Knochenmarks. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 309 REI2006a
  48. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. Journal of clinical oncology 2006, 24: 3686 [PMID: 16877738] LAN2006
  49. Reinhardt D, Ritter J: Klassifikation der Leukämien und malignen Lymphome. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 647 [ISBN: 3540037020] REI2006
  50. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005, 19: 2030 [PMID: 16304570] CRE2005c
  51. Classen CF, Teigler-Schlegel A, Rottgers S, Reinhardt D, Dohner K, Debatin KM: AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Annals of hematology 2005, 84: 774 [PMID: 16044313] CLA2005b
  52. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ: In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005, 106: 3532 [PMID: 16051737] GOE2005b
  53. Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D, Creutzig U, Klingebiel T, Chanock SJ, Schwabe D: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005, 19: 1745 [PMID: 16107886] LEH2005a
  54. Langebrake C, Creutzig U, Reinhardt D: Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klinische Padiatrie 2005, 217: 126 [PMID: 15858703] LAN2005a
  55. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19: 1536 [PMID: 16015387] GOE2005a
  56. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. The Journal of pharmacology and experimental therapeutics 2005, 312: 346 [PMID: 15501994] PUH2005
  57. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D: Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry. Part B, Clinical cytometry 2005, 63: 1 [PMID: 15624201] LAN2005
  58. Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Sigmond J, Gibson BE, Creutzig U, Giaccone G, Kaspers GJ: Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. Journal of clinical pathology 2005, 58: 695 [PMID: 15976334] HUB2005
  59. Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, Schrauder A, Zimmermann M, Fleischhack G, Ludwig WD, Harbott J, Creutzig U: Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia 2005, 19: 1495 [PMID: 15920489] REI2005
  60. Goemans BF, Zwaan CM, Martinelli S, Harrell P, de Lange D, Carta C, Reinhardt D, Hahlen K, Creutzig U, Tartaglia M, Heinrich MC, Kaspers GJ: Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. British journal of haematology 2005, 130: 801 [PMID: 16115145] GOE2005
  61. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, Kaspers GL, Lessard M, Michaux L, Vyas P, van Wering E, Zwaan CM, Golub TR, Orkin SH: Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103: 3339 [PMID: 16492768] BOU2004
  62. Cloos J, Zwaan CM, Corthals SL, Goemans BF, Waisfisz Q, Creutzig U, Reinhardt D, Hählen K, Kaspers GJL: FLT3/Internal Tandem Duplication in Paired Presentation and Relapse Pediatric AML Samples. Blood 2004, 104[11], 30a. CLO2004

Chronische myeloische Leukämie

Studienliteratur CML

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E: Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert review of clinical pharmacology 2018, 11: 219 [PMID: 29076384] SUT2018a
  2. Suttorp M, Schulze P, Glauche I, Gaehring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C: Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 2018, ePup ahead of print [PMID: 29925908] SUT2018
  3. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M: Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016, 127: 392 [PMID: 26511135] HIJ2016
  4. Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I: Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. Haematologica 2016, [PMID: 27856510] PRO2016
  5. de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F, International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee: Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. British journal of haematology 2014, 167: 33 [PMID: 24976289] FUE2014
  6. Ulmer A, Tabea Tauer J, Glauche I, Jung R, Suttorp M: TK Inhibitor Treatment Disrupts Growth Hormone Axis: Clinical Observations in Children with CML and Experimental Data from a Juvenile Animal Model. Klinische Padiatrie 2013, 225: 120 [PMID: 23716272] ULM2013
  7. Suttorp M, Eckardt L, Tauer JT, Millot F: Management of chronic myeloid leukemia in childhood. Current hematologic malignancy reports 2012, 7: 116 [PMID: 22395816] SUT2012
  8. Suttorp M, Yaniv I, Schultz KR: Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biology of blood and marrow transplantation 2011, 17(1 Suppl):S115 [PMID: 21195300] SUT2011
  9. Suttorp M, Millot F: Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology 2010, 368 [PMID: 21239821] SUT2010
  10. Schmid H, Jaeger B, Lohse J, Suttorp M: Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009, 94: 1177 [PMID: 19546438] SCH2009a